IV repeat-dose studies in rhesus monkeys (up to 2 months) and cynomolgus monkeys (up to 9 months)
“Repeated intravenous exposure to ibalizumab was studied up to 2 months in rhesus monkeys and up to 9 months in cynomolgus monkeys.”
✓ VerifiedEMA assessment report, p. 29Source ↗